Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049374 · ClinicalTrials.gov registry record · Phase 2
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049374: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT00049374 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049374, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in treating patients who have relapsed or refractory multiple myeloma.
Interventions
- DRUG dexamethasone
- BIOLOGICAL oblimersen sodium
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
What the finished NCT00049374 record still lists
NCT00049374 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00049374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049374 about?
NCT00049374 is a clinical study titled "Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in...
What is the current status of trial NCT00049374?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00049374?
The interventions under investigation include: dexamethasone (DRUG), oblimersen sodium (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00049374?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia